TY - JOUR
T1 - Sumoylation coordinates the repression of inflammatory and anti-viral gene-expression programs during innate sensing
AU - Decque, Adrien
AU - Joffre, Olivier
AU - Magalhaes, Joao G.
AU - Cossec, Jack Christophe
AU - Blecher-Gonen, Ronnie
AU - Lapaquette, Pierre
AU - Silvin, Aymeric
AU - Manel, Nicolas
AU - Joubert, Pierre Emmanuel
AU - Seeler, Jacob Sebastian
AU - Albert, Matthew L.
AU - Amit, Ido
AU - Amigorena, Sebastian
AU - Dejean, Anne
N1 - Institut National du Cancer [PLBIO13-057]; Agence Nationale de la Recherche [ANR-14-CE16]; Ligue Nationale Contre le Cancer (Equipes labellisees); Fondation pour la Recherche Medicale (FRM) [AJE201212]; Region-Midi-Pyrenees [NVEQ 2014]; European Research Council ('SUMOSTRESS'); European Research Council ('HIVINNATE') [309848]; European Research Council [DC-BIOX340046]; Ecole Normale Superieure; Odyssey-REWe thank M. Dasso (US National Institutes of Health) for antibody to SUMO-2; A. Garcia-Sastre(Icahn School of Medicine at Mount Sinai) for antibody to HA; A. Andrieux and J.-M. Carpier for technical help; Philippe Sansonetti (Pasteur Institute, Paris) for S. flexneri; and M. Yaniv for critical reading of the manuscript. Sequencing was performed by the Institut Genetique Biologie Moleculaire Cellulaire Microarray and Sequencing platform, a member of the 'France Genomique' consortium (ANR-10-INBS-0009). Supported by Institut National du Cancer (PLBIO13-057 to S.A.), Agence Nationale de la Recherche (ANR-14-CE16 to S.A.), Ligue Nationale Contre le Cancer (Equipes labellisees, A. Dejean and S.A.), Fondation pour la Recherche Medicale (FRM, AJE201212 to O.J.), Region-Midi-Pyrenees (NVEQ 2014 to O.J.), European Research Council ('SUMOSTRESS' to A. Dejean, 'DC-BIOX340046' to S.A., and 'HIVINNATE' (309848) to N.M.), Ecole Normale Superieure (A. Decque) and Odyssey-RE (A. Decque). We thank M. Dasso (US National Institutes of Health) for antibody to SUMO-2; A. Garcia-Sastre(Icahn School of Medicine at Mount Sinai) for antibody to HA; A. Andrieux and J.-M. Carpier for technical help; Philippe Sansonetti (Pasteur Institute, Paris) for S. flexneri; and M. Yaniv for critical reading of the manuscript. Sequencing was performed by the Institut Genetique Biologie Moleculaire Cellulaire Microarray and Sequencing platform, a member of the 'France Genomique' consortium (ANR-10-INBS-0009). Supported by Institut National du Cancer (PLBIO13-057 to S.A.), Agence Nationale de la Recherche (ANR-14-CE16 to S.A.), Ligue Nationale Contre le Cancer (Equipes labellisees, A. Dejean and S.A.), Fondation pour la Recherche Medicale (FRM, AJE201212 to O.J.), Region-Midi-Pyrenees (NVEQ 2014 to O.J.), European Research Council ('SUMOSTRESS' to A. Dejean, 'DC-BIOX340046' to S.A., and 'HIVINNATE' (309848) to N.M.), Ecole Normale Superieure (A. Decque) and Odyssey-RE (A. Decque).
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Innate sensing of pathogens initiates inflammatory cytokine responses that need to be tightly controlled. We found here that after engagement of Toll-like receptors (TLRs) in myeloid cells, deficient sumoylation caused increased secretion of transcription factor NF- B-dependent inflammatory cytokines and a massive type I interferon signature. In mice, diminished sumoylation conferred susceptibility to endotoxin shock and resistance to viral infection. Overproduction of several NF- B-dependent inflammatory cytokines required expression of the type I interferon receptor, which identified type I interferon as a central sumoylation-controlled hub for inflammation. Mechanistically, the small ubiquitin-like modifier SUMO operated from a distal enhancer of the gene encoding interferon-β (Ifnb1) to silence both basal and stimulus-induced activity of the Ifnb1 promoter. Therefore, sumoylation restrained inflammation by silencing Ifnb1 expression and by strictly suppressing an unanticipated priming by type I interferons of the TLR-induced production of inflammatory cytokines.
AB - Innate sensing of pathogens initiates inflammatory cytokine responses that need to be tightly controlled. We found here that after engagement of Toll-like receptors (TLRs) in myeloid cells, deficient sumoylation caused increased secretion of transcription factor NF- B-dependent inflammatory cytokines and a massive type I interferon signature. In mice, diminished sumoylation conferred susceptibility to endotoxin shock and resistance to viral infection. Overproduction of several NF- B-dependent inflammatory cytokines required expression of the type I interferon receptor, which identified type I interferon as a central sumoylation-controlled hub for inflammation. Mechanistically, the small ubiquitin-like modifier SUMO operated from a distal enhancer of the gene encoding interferon-β (Ifnb1) to silence both basal and stimulus-induced activity of the Ifnb1 promoter. Therefore, sumoylation restrained inflammation by silencing Ifnb1 expression and by strictly suppressing an unanticipated priming by type I interferons of the TLR-induced production of inflammatory cytokines.
UR - http://www.scopus.com/inward/record.url?scp=84955189761&partnerID=8YFLogxK
U2 - 10.1038/ni.3342
DO - 10.1038/ni.3342
M3 - مقالة
SN - 1529-2908
VL - 17
SP - 140
EP - 149
JO - Nature Immunology
JF - Nature Immunology
IS - 2
ER -